Skip to main navigation
Skip to search
Skip to main content
University of Kentucky Home
LOGIN & Help
Home
Research units
Researchers
Projects & Grants
Research Output
Facilities & Equipment
Honors & Awards
Activities
Search by expertise, name or affiliation
Number of patients that are able to be weaned off all third-line agents prior to the end of the SAGE-547 or placebo infusion, and remain off all third-line agents for = 24 hours following the end of the SAGE-547 or placebo infusion
Bensalem Owen, Meriem
(PI)
Neurology
Neuroscience Research Priority Area
Overview
Grants and Contracts Details
Status
Finished
Effective start/end date
7/13/15
→
4/18/18
Funding
Sage Therapeutics Incorporated:
$16,711.00
View all
View less